They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...